TD Cowen and BMO Capital are acting as joint book running managers for the offering. The deal priced inside the $3.25-$3.50 target range.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine Halts Sales Agreement Prospectus
- Prime Medicine announces common stock offering, no amount given
- Largest borrow rate increases among liquid names
- Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements
- Prime Medicine announces additional funding of up to $24M from CF Foundation